Knight 2nd J, Ene A, El Khouli R, Myint Z, Clair W
Cureus. 2024; 16(9):e69282.
PMID: 39398808
PMC: 11470835.
DOI: 10.7759/cureus.69282.
Yu E, Hwang M, Aragon-Ching J
Res Rep Urol. 2023; 15:519-529.
PMID: 38050587
PMC: 10693764.
DOI: 10.2147/RRU.S386517.
Zhu J, Zhang J, Hu P, Fan M, Song D, Yin H
Biochem Genet. 2023; 61(6):2242-2259.
PMID: 37010714
PMC: 10665256.
DOI: 10.1007/s10528-023-10367-z.
Kim M, Ku J, Hong S, Kim H, Kwon Y, Park J
Front Pharmacol. 2021; 12:683575.
PMID: 34054558
PMC: 8155384.
DOI: 10.3389/fphar.2021.683575.
Mirsafaei R, Varshosaz J
IET Nanobiotechnol. 2020; 14(5):417-422.
PMID: 32691745
PMC: 8676636.
DOI: 10.1049/iet-nbt.2020.0014.
Isolated Hepatic Metastasis from Prostate Carcinoma.
Wang S, McCarthy L, Mehdi S
Urol Case Rep. 2016; 10:51-53.
PMID: 27957428
PMC: 5148773.
DOI: 10.1016/j.eucr.2016.11.012.
Factors associated with the survival of prostate cancer patients with rectal involvement.
Wang H, Yao Y, Li B
Diagn Pathol. 2014; 9:35.
PMID: 24555830
PMC: 3938032.
DOI: 10.1186/1746-1596-9-35.
Clinical characteristics and prognostic factors of prostate cancer with liver metastases.
Wang H, Li B, Zhang P, Yao Y, Chang J
Tumour Biol. 2013; 35(1):595-601.
PMID: 23959476
DOI: 10.1007/s13277-013-1083-6.
The role of micro RNAs let7c, 100 and 218 expression and their target RAS, C-MYC, BUB1, RB, SMARCA5, LAMB3 and Ki-67 in prostate cancer.
Reis S, Timoszczuk L, Pontes-Junior J, Viana N, Silva I, Dip N
Clinics (Sao Paulo). 2013; 68(5):652-7.
PMID: 23778407
PMC: 3654318.
DOI: 10.6061/clinics/2013(05)12.
Brain metastases from prostate cancer: an 11-year analysis in the MRI era with emphasis on imaging characteristics, incidence, and prognosis.
Hatzoglou V, Patel G, Morris M, Curtis K, Zhang Z, Shi W
J Neuroimaging. 2013; 24(2):161-6.
PMID: 23279641
PMC: 4724409.
DOI: 10.1111/j.1552-6569.2012.00767.x.
Differential expression of matrix metalloproteinase-2 expression in disseminated tumor cells and micrometastasis in bone marrow of patients with nonmetastatic and metastatic prostate cancer: theoretical considerations and clinical implications-an....
Murray N, Reyes E, Tapia P, Badinez L, Orellana N
Bone Marrow Res. 2012; 2012:259351.
PMID: 23227342
PMC: 3513718.
DOI: 10.1155/2012/259351.
AgNOR quantity in needle biopsy specimens of prostatic adenocarcinomas: correlation with proliferation state, Gleason score, clinical stage, and DNA content.
Trere D, Zilbering A, Dittus D, Kim P, Ginsberg P, Daskal I
Clin Mol Pathol. 1996; 49(4):M209-13.
PMID: 16696076
PMC: 408060.
DOI: 10.1136/mp.49.4.m209.
Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes.
Pinthus J, Waks T, Malina V, Kaufman-Francis K, Harmelin A, Aizenberg I
J Clin Invest. 2004; 114(12):1774-81.
PMID: 15599402
PMC: 535069.
DOI: 10.1172/JCI22284.
Background to and management of treatment-related bone loss in prostate cancer.
Berruti A, Tucci M, Terrone C, Gorzegno G, Scarpa R, Angeli A
Drugs Aging. 2002; 19(12):899-910.
PMID: 12495366
DOI: 10.2165/00002512-200219120-00002.
Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.
Mahler C, Verhelst J, Denis L
Clin Pharmacokinet. 1998; 34(5):405-17.
PMID: 9592622
DOI: 10.2165/00003088-199834050-00005.
Induction of transforming growth factor beta in hormonally treated human prostate cancer.
Muir G, Butta A, Shearer R, Fisher C, Dearnaley D, Flanders K
Br J Cancer. 1994; 69(1):130-4.
PMID: 8286194
PMC: 1968789.
DOI: 10.1038/bjc.1994.21.
Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer.
Ware J
Cancer Metastasis Rev. 1993; 12(3-4):287-301.
PMID: 8281614
DOI: 10.1007/BF00665959.
Cell proliferation in prostatic carcinoma: comparative analysis of Ki-67, MIB-1 and PCNA.
Hepburn P, Goddard L, Gee J, Harper M
Histochem J. 1995; 27(3):196-203.
PMID: 7797424
Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia.
Hamdy F, Fadlon E, Cottam D, Lawry J, Thurrell W, Silcocks P
Br J Cancer. 1994; 69(1):177-82.
PMID: 7506923
PMC: 1968786.
DOI: 10.1038/bjc.1994.30.
Screening for prostate cancer. How can patients give informed consent?.
Marshall K
Can Fam Physician. 1993; 39:2385-90.
PMID: 7505673
PMC: 2379946.
